Psychedelic Drug Discovery Incubator


Our mission
To advance the field of psychedelics and improve access to life-saving treatments by funding and supporting the development of innovative therapies from pre-clinical studies through Phase I clinical trials.
We strive to bridge the gap between early-stage research and commercialization and to create a positive impact on the lives of patients around the world.
Our focus
Supporting the development of innovative treatments from pre-clinical studies through Phase I clinical trials.
ABOUT Negev labs
Negev Labs serves as an engine to fund early-stage research in the psychedelic space.
Our goal
To license out drug candidates to the leading players in the psychedelic space and to large pharmaceutical companies, thus allowing for further development and eventual commercialization of these promising treatments.
Our team
We bring a wealth of expertise, experience, and industry relationships, and we use cutting-edge technology to support navigating the complex world of drug development.
With a commitment to excellence, our drug development platform will help advance the field of psychedelic medicine.
NCE design and in silico molecule structure
What Do We Offer?
Project management and advisory
Funding of research and pre-clinical studies
FTO and IP validation
Selection and contracting CMO
In vitro pharmacology
NCEs improvement, initial toxicology, and solubility tests
ADME/PK assays
In vivo HTR and Screening Tests for Potential Therapeutic Efficacy
Principal Therapeutic Target: Negative symptoms of Schizophrenia
Collaboration agreement with Hadassah Brain Labs (Israel) and Professor Bernard Lerer.
Going Beyond Psilocybin — Creating the Next Generation of Psychedelic Drugs for Ethical Use in Medicine
Collaboration agreement with Prof. Alan Kozikowski
Management team
Principal at Negev Capital since 2022.

Dr. Adamsky has a long-demonstrated track record in pharmaceutical R&D.

He served as a VP Operations and Technology at Levco Pharmaceuticals Ltd, CEO and VP Operations at Regenera Pharma LTD, Director and co-CEO at Targia Pharmaceuticals, Co-founder and Director of Celleska Pty, Australian Cell & Gene Therapy Incubator. Dr. Adamsky has also held positions at Compugen and the Weizmann Institute of Science.

Dr. Adamsky holds his Ph.D. from the Weizmann Institute of Science.
Kostia Adamsky
Advisory board
Chair of the Advisory Board
Partner at Negev Capital since 2021.

Founded and operates an outpatient psychiatry clinicin New York Cityand teaches psychiatry at the Chaim Sheba Medical Center in Israel.

Graduated at medical school at Emory University, interned at the University of Pennsylvania, and trained in epidemiologyat the US Centers for Disease Control. Residencyin psychiatry and a fellowshipin psychopharmacology at Columbia University.

Served as attending physician at Columbia for 15 years, with aresearch focus on the role of androgens in CNS function.
Stuart Seidman
Dr. Kozikowski is world renowned for his work in the area of medicinal chemistry designing NCEs for both cancer and CNS disorders. He has over 550 publications and 100 patents.

He trained at the University of Michigan, Berkeley, and Harvard, worked for 40+ years as a Professor at the University of Pittsburgh, the Mayo Clinic, the Georgetown University Medical Center, and was the Director of the Drug Discovery Program at the University of Illinois, Chicago.

Dr. Kozikowski is a founder of Actuate Therapeutics (pancreatic cancer drug in Phase 2), Bright Minds Biosciences (epilepsy drug in Phase 1) and is now setting up StarWise Psychedelics to advance the use of 5-HT2A agonists for neurological and psychiatric disorders.
Alan Kozikowski
Graham Pechenik is a registered patent attorney and the founder of Calyx Law, where he works with cannabis and psychedelics ventures to design and implement their IP strategies.

Graham has a BS in Cognitive Neuroscience and Biochemistry from UCSD and a JD from NYU, and began his career with a decade at large law firms representing Fortune 500 companies across the agricultural, chemical, pharmaceutical, biotech, and technology industries, including on numerous landmark patent cases at trial and on appeal. Graham also contributes to Psychedelics Alpha as editor-at-large.
Graham Pechenik
and we will contact you
or you can find us in social media:
* By clicking the button you consent to the processing of personal data.
8 The Green, Ste A, Dover, 19901, Delaware, USA